TP53 Y220C is a specific hotspot mutation of the TP53 (Tumor Protein p53) gene, where the 220th amino acid tyrosine (Tyr, Y) is replaced by cysteine (Cys, C), hence named Y220C. This mutation occurs in the core DNA-binding domain of the p53 protein, leading to significant structural alterations and loss of function. It is a common mutation found in many human cancers, particularly in solid tumors such as lung cancer, breast cancer, and colorectal cancer.
Ba/F3 cells are a cell line derived from murine bone marrow-dependent pre-B cells, which typically rely on IL-3 (interleukin-3) for survival and proliferation. When a mutant TP53 gene is introduced, these cells become independent of IL-3 and begin to proliferate through TP53-mediated signaling pathways. Therefore, TP53 Ba/F3 cells are a classic tool for validating the oncogenic activity of TP53 mutations and are also suitable for screening TP53 inhibitors.
Genomeditech provides Ba/F3 cell lines targeting TP53 and other related targets, supporting the screening, activity validation, and in vitro efficacy studies of TP53 inhibitors.
